Efficacy and safety of standard and low dose ticagrelor versus clopidogrel in east AsianPatients with chronic total occlusion undergoing percutaneous coronary intervention: a single center retrospective study | BMC Cardiovascular Disorders
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI - ScienceDirect
Ticagrelor (Brilinta) for Secondary Prevention of Thrombotic Events Following Acute Coronary Syndrome - STEPS - American Family Physician
JCM | Free Full-Text | Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial | HTML
Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark - The Lancet Regional Health – Europe
Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4 | tctmd.com
Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial
Transition between ticagrelor and two different doses of clopidogrel at hospital discharge in patients with acute coronary syndrome submitted to percutaneous coronary intervention | Revista Brasileira de Cardiologia Invasiva (English Edition)
Double Versus Standard Loading Dose of Ticagrelor: Onset of Antiplatelet Action in Patients With STEMI Undergoing Primary PCI | Journal of the American College of Cardiology
Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial | Trials | Full Text
Dr. Sheila Sahni on Twitter: "Algorithm for switching between oral P2Y12 inhibitors in the acute and chronic setting. (For the Figure: LD = loading dose; MD = maintenance dose) Source: 2017 ESC
Double (360mg) Loading Dose Of Ticagrelor In Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention | tctmd.com
Figure 1 from Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. | Semantic Scholar
Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada - CJC Open
Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention - American Journal of Cardiology
Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week - ScienceDirect
2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy - Canadian Journal of Cardiology
Dosing & Administration | BRILINTA® (ticagrelor) tablets | For HCPs
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
2 3 De escalation strategies
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI | JACC: Cardiovascular Interventions
